APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry
- PMID: 37930705
- PMCID: PMC10628838
- DOI: 10.1001/jamaneurol.2023.3599
APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry
Abstract
Importance: Apolipoprotein E (APOE)*2 and APOE*4 are, respectively, the strongest protective and risk-increasing, common genetic variants for late-onset Alzheimer disease (AD), making APOE status highly relevant toward clinical trial design and AD research broadly. The associations of APOE genotypes with AD are modulated by age, sex, race and ethnicity, and ancestry, but these associations remain unclear, particularly among racial and ethnic groups understudied in the AD and genetics research fields.
Objective: To assess the stratified associations of APOE genotypes with AD risk across sex, age, race and ethnicity, and global population ancestry.
Design, setting, participants: This genetic association study included case-control, family-based, population-based, and longitudinal AD-related cohorts that recruited referred and volunteer participants. Data were analyzed between March 2022 and April 2023. Genetic data were available from high-density, single-nucleotide variant microarrays, exome microarrays, and whole-exome and whole-genome sequencing. Summary statistics were ascertained from published AD genetic studies.
Main outcomes and measures: The main outcomes were risk for AD (odds ratios [ORs]) and risk of conversion to AD (hazard ratios [HRs]), with 95% CIs. Risk for AD was evaluated through case-control logistic regression analyses. Risk of conversion to AD was evaluated through Cox proportional hazards regression survival analyses.
Results: Among 68 756 unique individuals, analyses included 21 852 East Asian (demographic data not available), 5738 Hispanic (68.2% female; mean [SD] age, 75.4 [8.8] years), 7145 non-Hispanic Black (hereafter referred to as Black) (70.8% female; mean [SD] age, 78.4 [8.2] years), and 34 021 non-Hispanic White (hereafter referred to as White) (59.3% female; mean [SD] age, 77.0 [9.1] years) individuals. There was a general, stepwise pattern of ORs for APOE*4 genotypes and AD risk across race and ethnicity groups. Odds ratios for APOE*34 and AD risk attenuated following East Asian (OR, 4.54; 95% CI, 3.99-5.17),White (OR, 3.46; 95% CI, 3.27-3.65), Black (OR, 2.18; 95% CI, 1.90-2.49) and Hispanic (OR, 1.90; 95% CI, 1.65-2.18) individuals. Similarly, ORs for APOE*22+23 and AD risk attenuated following White (OR, 0.53, 95% CI, 0.48-0.58), Black (OR, 0.69, 95% CI, 0.57-0.84), and Hispanic (OR, 0.89; 95% CI, 0.72-1.10) individuals, with no association for Hispanic individuals. Deviating from the global pattern of ORs, APOE*22+23 was not associated with AD risk in East Asian individuals (OR, 0.97; 95% CI, 0.77-1.23). Global population ancestry could not explain why Hispanic individuals showed APOE associations with less pronounced AD risk compared with Black and White individuals. Within Black individuals, decreased global African ancestry or increased global European ancestry showed a pattern of APOE*4 dosage associated with increasing AD risk, but no such pattern was apparent for APOE*2 dosage with AD risk. The sex-by-age-specific interaction effect of APOE*34 among White individuals (higher risk in women) was reproduced but shifted to ages 60 to 70 years (OR, 1.48; 95% CI, 1.10-2.01) and was additionally replicated in a meta-analysis of Black individuals and Hispanic individuals (OR, 1.72; 95% CI, 1.01-2.94).
Conclusion and relevance: Through recent advances in AD-related genetic cohorts, this study provided the largest-to-date overview of the association of APOE with AD risk across age, sex, race and ethnicity, and population ancestry. These novel insights are critical to guide AD clinical trial design and research.
Conflict of interest statement
Figures
Comment on
-
APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-β.JAMA Neurol. 2023 Dec 1;80(12):1269-1271. doi: 10.1001/jamaneurol.2023.4046. JAMA Neurol. 2023. PMID: 37930662 No abstract available.
Similar articles
-
Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.JAMA. 1997 Oct 22-29;278(16):1349-56. JAMA. 1997. PMID: 9343467
-
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease.JAMA Neurol. 2022 Jul 1;79(7):652-663. doi: 10.1001/jamaneurol.2022.1166. JAMA Neurol. 2022. PMID: 35639372 Free PMC article.
-
Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease.JAMA. 2023 Feb 21;329(7):551-560. doi: 10.1001/jama.2023.0268. JAMA. 2023. PMID: 36809323 Free PMC article.
-
Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.JAMA Neurol. 2020 Jul 1;77(7):849-862. doi: 10.1001/jamaneurol.2020.0414. JAMA Neurol. 2020. PMID: 32282020 Free PMC article.
-
Association of apolipoprotein E genetic variation in Alzheimer's disease in Indian population: a meta-analysis.Am J Alzheimers Dis Other Demen. 2014 Nov;29(7):575-82. doi: 10.1177/1533317514531443. Am J Alzheimers Dis Other Demen. 2014. PMID: 25551132 Free PMC article. Review.
Cited by
-
APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.Nat Med. 2024 May;30(5):1284-1291. doi: 10.1038/s41591-024-02931-w. Epub 2024 May 6. Nat Med. 2024. PMID: 38710950
-
Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer's disease.Acta Neuropathol. 2024 Apr 10;147(1):70. doi: 10.1007/s00401-024-02721-1. Acta Neuropathol. 2024. PMID: 38598053 Free PMC article.
-
Validation of the brain health index in the European Prevention of Alzheimer's Dementia cohort.Cereb Circ Cogn Behav. 2024 Feb 29;6:100214. doi: 10.1016/j.cccb.2024.100214. eCollection 2024. Cereb Circ Cogn Behav. 2024. PMID: 38595911 Free PMC article.
-
A comprehensive analysis of APOE genotype effects on human brain structure in the UK Biobank.Transl Psychiatry. 2024 Mar 12;14(1):143. doi: 10.1038/s41398-024-02848-5. Transl Psychiatry. 2024. PMID: 38472178 Free PMC article.
-
Controlled Variable Selection from Summary Statistics Only? A Solution via GhostKnockoffs and Penalized Regression.ArXiv [Preprint]. 2024 Feb 20:arXiv:2402.12724v1. ArXiv. 2024. PMID: 38463500 Free PMC article. Preprint.
References
-
- Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous